拉米夫定与阿德福韦酯联用治疗乙型病毒性肝炎肝硬化67例临床研究

A Clinical Study of the Combination of Lamivudine and Adefovir Dipivoxil in the Treatment of Hepatitis B Cirrhosis

目的:探讨拉米夫定与阿德福韦酯联用治疗乙型病毒性肝炎肝硬化的治疗效果。方法:选取2005年1月至2010年8月134例乙型病毒性肝炎肝硬化患者为研究对象,将其分为A组(拉米夫定与阿德福韦酯联用治疗组)67例和B组(阿德福韦酯治疗组)67例,将两组患者治疗后的门静脉内径、脾厚度以及治疗前后HBV-DNA载量情况进行统计及比较。结果:A组患者治疗后的门静脉内径、脾厚度以及治疗前后HBV-DNA载量情况明显优于B组(P<0.05)。结论:拉米夫定与阿德福韦酯联用治疗乙型病毒性肝炎肝硬化的临床效果好,能够有效提高肝功能,使HBV-DNA载量有效降低,值得临床推广应用。

Objective： To evaluate the curative effect of the combination of lamivudine and adefovir dipivoxil in the treatment of the hepatitis B cirrhosis.Methods： From January 2005 to August 2010,134 patients with hepatitis B cirrhosis were randomly divided into group A（n=67）treated with the combination of lamivudine and adefovir dipivoxil and group B（n=67）treated with adefovir dipivoxil alone.After treatment,the diameter of the portal vein,the thickness of spleen and the level of serum hepatitis B virus DNA were recorded and analysized.Results： In group A,the diameter of the portal vein,the thickness of spleen and the level of serum hepatitis B virus DNA were all superior to those in group B.There was a significant difference between the two groups（P0.05）.Conclusion： In the treatment of hepatitis B cirrhosis,application of combination of lamivudine and adefovir dipivoxil can result superior outcomes and promote the liver function as well.